Technical Analysis for WVE - WAVE Life Sciences Ltd.

Grade Last Price % Change Price Change
grade C 44.0 1.71% 0.74
WVE closed up 1.71 percent on Wednesday, January 16, 2019, on 2.25 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Flat Up Up
See historical WVE trend table...

Date Alert Name Type % Chg
Jan 16 200 DMA Resistance Bearish 0.00%
Jan 16 Crossed Above 50 DMA Bullish 0.00%
Jan 16 Pocket Pivot Bullish Swing Setup 0.00%
Jan 16 Narrow Range Bar Range Contraction 0.00%
Jan 16 NR7 Range Contraction 0.00%
Jan 16 Up 3 Days in a Row Strength 0.00%
Jan 15 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.71%
Jan 15 20 DMA Support Bullish 1.71%
Jan 14 Crossed Above 20 DMA Bullish 4.22%
Jan 11 20 DMA Resistance Bearish 5.92%

Older signals for WVE ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
WAVE Life Sciences Pte. Ltd., a preclinical biopharmaceutical company, designs, develops, and commercializes nucleic acid therapeutic candidates. The company is developing nucleic acid therapeutics that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. Its advanced therapeutic programs are in Huntington's disease, Duchenne muscular dystrophy (DMD), and inflammatory bowel disease (IBD). In Huntington's disease, it has programs targeting HTT SNP-1 and HTT SNP-2; in DMD, targeting Exon 51; and in IBD, targeting SMAD7. The company also has product candidates in its programs targeting HTT SNP-1 and Exon 51. In addition, it has late-stage discovery programs in epidermolysis bullosa simplex, targeting KRT14 SNP-1 and KRT14 SNP-2, as well as in DMD, focuses on an additional DMD target, AcRIIb. The company was founded in 2012 and is based in Singapore.
Is WVE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 56.0
52 Week Low 32.25
Average Volume 158,041
200-Day Moving Average 44.1138
50-Day Moving Average 43.5178
20-Day Moving Average 41.663
10-Day Moving Average 42.224
Average True Range 2.8818
ADX 16.69
+DI 19.8789
-DI 21.881
Chandelier Exit (Long, 3 ATRs ) 42.3346
Chandelier Exit (Short, 3 ATRs ) 43.0254
Upper Bollinger Band 46.4548
Lower Bollinger Band 36.8712
Percent B (%b) 0.74
BandWidth 23.002664
MACD Line -0.354
MACD Signal Line -0.6849
MACD Histogram 0.3309
Fundamentals Value
Market Cap 1.22 Billion
Num Shares 27.8 Million
EPS -3.35
Price-to-Earnings (P/E) Ratio -13.13
Price-to-Sales 250.07
Price-to-Book 3.20
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 45.98
Resistance 3 (R3) 45.86 45.09 45.65
Resistance 2 (R2) 45.09 44.58 45.15 45.54
Resistance 1 (R1) 44.54 44.27 44.82 44.66 45.43
Pivot Point 43.77 43.77 43.90 43.83 43.77
Support 1 (S1) 43.22 43.26 43.50 43.34 42.57
Support 2 (S2) 42.45 42.95 42.51 42.46
Support 3 (S3) 41.90 42.45 42.35
Support 4 (S4) 42.02